Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mutant Advanced NSCLC: Longer Follow-Up of the MARIPOSA Study : Episode 4

Amivantamab Plus Lazertinib Added to NCCN for Frontline NSCLC

October 22, 2024

By Joshua K. Sabari, MD
Sandip Patel, MD

Opinion

Video

Panelists discuss the National Comprehensive Cancer Network (NCCN) guidelines for first-line treatment of EGFR-mutant metastatic non–small cell lung cancer (NSCLC), emphasizing the recommended therapies and best practices for patient management.

EP: 1.Overview of MARIPOSA Study

EP: 2.Amivantamab Plus Lazertinib Clinical Efficacy

EP: 3.Safety Considerations for Frontline Amivantamab Plus Lazertinib

Now Viewing

EP: 4.Amivantamab Plus Lazertinib Added to NCCN for Frontline NSCLC

EP: 5.Putting Amivantamab Plus Lazertinib Into Practice

EP: 6.Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!